Mirogabalin - the use of a new gabapentinoid in the treatment of diabetic neuropathy and postherpetic neuropathy and other conditions
DOI:
https://doi.org/10.12775/QS.2023.09.01.007Keywords
mirogabalin, neuropathy, pregabalinAbstract
Introduction: Mirogabalin is a new drug from the gabapentinoid group first registered in Japan in 2019. It has found use in the treatment of peripheral neuropathic pain in diabetic neuropathy and postherpetic neuropathy.
Purpose: In this article, we review studies on the efficacy and safety of mirogabalin in the treatment of registered indications and its potentially new applications.
Materials and Methods: We reviewed the literature available in the PubMed database, using the key words: "mirogabalin", "neuropathy" "pregabalin".
Results: Mirogabalin has been registered for the treatment of neuropathic pain in diabetic neuropathy and postherpetic neuropathy. The literature shows that it is effective and safe in the above-mentioned indications. Its use has also been described: in the treatment of neuropathic pain of other etiologies with intolerance to pregabalin, as a coanalgesic in the treatment of pain in the course of cancer, and in neuropathy caused by chemotherapy. It has been shown to be effective in all of the aforementioned cases. Studies have shown no clinically significant effect of mirogabalin in the symptomatic treatment of fibromyalgia pain. It has a good safety profile and a low number of adverse effects.
Conclusions:. Mirogabalin is a drug that has the potential to improve the efficacy of treatment of neuropathic pain due to various causes. There is a need to continue conducting studies on larger groups of patients in order to make wider use of its potential in clinical practice.
References
van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014 Apr;155(4):654-662. doi: 10.1016/j.pain.2013.11.013. Epub 2013 Nov 26. Erratum in: Pain. 2014 Sep;155(9):1907. PMID: 24291734.
Zajączkowska R, Mika J, Leppert W, Kocot-Kępska M, Malec-Milewska M, Wordliczek J. Mirogabalin-A Novel Selective Ligand for the α2δ Calcium Channel Subunit. Pharmaceuticals (Basel). 2021 Jan 31;14(2):112. doi: 10.3390/ph14020112. PMID: 33572689; PMCID: PMC7911728.
Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, Kadurin I, Sri Ranjan Y, Fernandez-Alacid L, Millar NS, Dickenson AH, Lujan R, Dolphin AC. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci. 2009 Apr 1;29(13):4076-88. doi: 10.1523/JNEUROSCI.0356-09.2009. PMID: 19339603; PMCID: PMC6665374.
Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci. 2004 Sep;20(6):1566-76. doi: 10.1111/j.1460-9568.2004.03625.x. PMID: 15355323.
Tran-Van-Minh A, Dolphin AC. The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2. J Neurosci. 2010 Sep 22;30(38):12856-67. doi: 10.1523/JNEUROSCI.2700-10.2010. PMID: 20861389; PMCID: PMC6633565.
Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, Kai K, Kitano Y. Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the α2δ Subunit of Voltage-Gated Calcium Channels. J Pharmacol Exp Ther. 2018 Jun;365(3):573-582. doi: 10.1124/jpet.117.247551. Epub 2018 Mar 21. PMID: 29563324.
Yin OQ, Merante D, Truitt K, Miller R. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. J Clin Pharmacol. 2016;56(2):203–12. doi: 10.1002/jcph.584.
Duchin K, Senaldi G, Warren V, Marbury T, Lasseter K, Zahir H. Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin. Clin Drug Investig. 2018;38(11):1001–9. doi: 10.1007/s40261-018-0692-7
Dow J, Currie A, He L, Zaidi F, Zahir H. Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study. Int J Clin Pharmacol Ther. 2018;56(10):451–8. doi: 10.5414/CP203185.
Sadosky A, Mardekian J, Parsons B, Hopps M, Bienen EJ, Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015 Mar;29(2):212-7. doi: 10.1016/j.jdiacomp.2014.10.013. Epub 2014 Nov 8. PMID: 25498300.
Yang M, Qian C, Liu Y. Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United States. Pain Med. 2015 Nov;16(11):2075-83. doi: 10.1111/pme.12845. Epub 2015 Jun 27. PMID: 26118704.
Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig. 2020 May;11(3):693-698. doi: 10.1111/jdi.13178. Epub 2019 Dec 25. PMID: 31722446; PMCID: PMC7232295.
Mendell J, Levy-Cooperman N, Sellers E, Vince B, Kelsh D, Lee J, Warren V, Zahir H. Abuse potential of mirogabalin in recreational polydrug users. Ther Adv Drug Saf. 2019 Apr 5;10:2042098619836032. doi: 10.1177/2042098619836032. PMID: 31057786; PMCID: PMC6452577.
Alyoubi RA, Alshareef AA, Aldughaither SM, Aljaroudi AM, Alabdulwahed A, Alduraibi FM, Masoud AT, Abu-Zaid A. Efficacy and safety of mirogabalin treatment in patients with diabetic peripheral neuropathic pain: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021 May;75(5):e13744. doi: 10.1111/ijcp.13744. Epub 2020 Oct 27. PMID: 32991782.
Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients: Erratum. Pain. 2019 Aug;160(8):1905. doi: 10.1097/j.pain.0000000000001645. Erratum for: Pain. 2019 May;160(5):1175-1185. PMID: 31335662; PMCID: PMC7144746.
Tetsunaga T, Tetsunaga T, Nishida K, Misawa H, Takigawa T, Yamane K, Tsuji H, Takei Y, Ozaki T. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study. J Orthop Surg Res. 2020 May 26;15(1):191. doi: 10.1186/s13018-020-01709-3. PMID: 32456647; PMCID: PMC7249688.
Nakanishi K, Ota C, Yomiya K. [Analgesic Effects of Mirogabalin for Cancer Pain]. Gan To Kagaku Ryoho. 2020 Jun;47(6):927-931. Japanese. PMID: 32541170.
Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Okubo Y, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021 Dec 9;21(1):1319. doi: 10.1186/s12885-021-09069-9. PMID: 34886831; PMCID: PMC8656082.
Yang K, Wang Y, Li YW, Chen YG, Xing N, Lin HB, Zhou P, Yu XP. Progress in the treatment of diabetic peripheral neuropathy. Biomed Pharmacother. 2022 Apr;148:112717. doi: 10.1016/j.biopha.2022.112717. Epub 2022 Feb 19. PMID: 35193039.
Statistics OfN. Deaths related to drug poisoning in England and Wales: 2016 registrations 2017. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2016registrations—people-aged-40-to-49-years-have-the-highest-rate-of-drug-misuse-deaths.
Azmi S, ElHadd KT, Nelson A, Chapman A, Bowling FL, Perumbalath A, Lim J, Marshall A, Malik RA, Alam U. Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review. Diabetes Ther. 2019 Feb;10(1):35-56. doi: 10.1007/s13300-018-0550-x. Epub 2018 Dec 18. PMID: 30565054; PMCID: PMC6349275.
Gruver C, Guthmiller KB. Postherpetic Neuralgia. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 29630250.
Jordan, Roberta I.; Mulvey, Matthew R.; Bennett, Michael I.. A critical appraisal of gabapentinoids for pain in cancer patients. Current Opinion in Supportive and Palliative Care 12(2):p 108-117, June 2018. | DOI: 10.1097/SPC.0000000000000337
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019 Mar 22;20(6):1451. doi: 10.3390/ijms20061451. PMID: 30909387; PMCID: PMC6471666.
Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncol Ther. 2021 Dec;9(2):385-450. doi: 10.1007/s40487-021-00168-y. Epub 2021 Oct 16. PMID: 34655433; PMCID: PMC8593126.
Merante D. The mirogabalin ALDAY phase 3 program in pain associated with fibromyalgia: the lessons learned. Curr Med Res Opin. 2020;36(4):661–6. doi: 10.1080/03007995.2020.1725744.
Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021 Apr 9;22(8):3891. doi: 10.3390/ijms22083891. PMID: 33918736; PMCID: PMC8068842.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Weronika Gawel, Sylwia Zdun, Klaudia Walczak, Zuzanna Wesołowska, Przemysław Jędruszczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 565
Number of citations: 0
